[6] Prior to 1987, Abingworth had made investments, considered by 2016 to have been successful, in Apple and Silicon Graphics.

[6][7] The firm has also provided funding to support the acquisition of Algeta by Bayer and Avila Therapeutics by Celgene.

[7][8][9][10] In the Algeta case, this was the very first of the firm's venture investments in public equities, dating to February 2009.

[6][7] It also, in January 2013, set up Avillion Group Partners, a clinical phase III co-development accelerator, with Massachusetts-based Clarus Ventures.

[1] The company also has a board of directors, which consisted of two members in 2016, Stephen Bunting and Theodore Clark.

[1] Bunting had been a managing partner from 2002 to at least 2014,[7] having joined Abingworth in 1987 after leaving Rothschild with Leathers.

[3]: 51  By 2014, Bunting had been involved in the establishment each of the ten (at that time) of the company's life science investment funds.